Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 28;8(5):501-517.
doi: 10.1093/nop/npab030. eCollection 2021 Oct.

Efficacy of antiepileptic drugs in glioma patients with epilepsy: a systematic review

Marjolein E de Bruin  1 , Pim B van der Meer  2 , Linda Dirven  1   2 , Martin J B Taphoorn  1   2 , Johan A F Koekkoek  1   2
Affiliations
Review

Efficacy of antiepileptic drugs in glioma patients with epilepsy: a systematic review

Marjolein E de Bruin et al. Neurooncol Pract. .

Abstract

Background: Comprehensive data on the efficacy and tolerability of antiepileptic drugs (AED) treatment in glioma patients with epilepsy are currently lacking. In this systematic review, we specifically assessed the efficacy of AEDs in patients with a grade II-IV glioma.

Methods: Electronic databases PubMed/MEDLINE, EMBASE, Web of Science, and Cochrane Library were searched up to June 2020. Three different outcomes for both mono- and polytherapy were extracted from all eligible articles: (i) seizure freedom; (ii) ≥50% reduction in seizure frequency; and (iii) treatment failure. Weighted averages (WA) were calculated for outcomes at 6 and 12 months.

Results: A total of 66 studies were included. Regarding the individual outcomes on the efficacy of monotherapy, the highest seizure freedom rate at 6 months was with phenytoin (WA = 72%) while at 12-month pregabalin (WA = 75%) and levetiracetam (WA = 74%) showed highest efficacy. Concerning ≥50% seizure reduction rates, levetiracetam showed highest efficacy at 6 and 12 months (WAs of 82% and 97%, respectively). However, treatment failure rates at 12 months were highest for phenytoin (WA = 34%) and pregabalin (41%). When comparing the described polytherapy combinations with follow-up of ≥6 months, levetiracetam combined with phenytoin was most effective followed by levetiracetam combined with valproic acid.

Conclusion: Given the heterogeneous patient populations and the low scientific quality across the different studies, seizure rates need to be interpreted with caution. Based on the current limited evidence, with the ranking of AEDs being confined to the AEDs studied, levetiracetam, phenytoin, and pregabalin seem to be most effective as AED monotherapy in glioma patients with epilepsy, with levetiracetam showing the lowest treatment failure rate, compared to the other AEDs studied.

Keywords: antiepileptic drugs; brain tumor; epilepsy; glioma; seizures.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Literature selection procedure.
Figure 2.
Figure 2.
Weighted average (WA) calculated for outcomes at 6 and 12 months.
See this image and copyright information in PMC

References

    1. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and ma nagem ent. Lancet Neurol. 2007;6(5):421–430.
    1. Kerkhof M, Vecht CJ. Seizure characteristics and prognostic factors of gliomas. Epilepsia. 2013;54(Suppl 9):12–17. - PubMed
    1. Liigant A, Haldre S, Oun A, et al. . Seizure disorders in patients with brain tumors. Eur Neurol. 2001;45(1):46–51. - PubMed
    1. Klein M, Engelberts NH, van der Ploeg HM, et al. . Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol. 2003;54(4):514–520. - PubMed
    1. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3(3):159–168. - PubMed